---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-060676"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2021-12-20T23:59:59+00:00"
generated_at: "2026-06-27T23:52:26.852061+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD appoints Hugh O'Dowd as CEO; founder Finizio becomes Vice Chair

## Summary
- Hugh O'Dowd, formerly President, appointed CEO on Dec 14, 2021 and director on Dec 18.
- Robert G. Finizio steps down as CEO but remains Vice Chair of the Board.
- Finizio's separation is termination without 'Cause'; he receives contractual separation benefits.
- O'Dowd's existing employment agreement (filed Aug 9, 2021) continues unchanged.

## SEC filing metadata
- accession: 0001564590-21-060676
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2021-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/txmd-8k_20211214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-060676
- JSON: https://secwatch.observer/filing/0001564590-21-060676.json
- Plain text: https://secwatch.observer/filing/0001564590-21-060676.txt

## Key facts
- Executive change
  Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On December 14, 2021, the board of directors (the “Board”) of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), appointed Mr. Hugh O’Dowd, the Company’s President, as the Company’s Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm
- Executive change
  Robert G. Finizio was terminated as Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: terminated
  - Role: Chief Executive Officer
  source text: Mr. Finizio’s separation as the Company’s Chief Executive Officer is a termination without “Cause,” as defined in that certain employment agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm
- Executive change
  Hugh O'Dowd was appointed as director at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: director
  source text: on December 18, 2021, the Board appointed Mr. O'Dowd as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459021060676/0001564590-21-060676-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.